← All trials
NCT04060342
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2019
- Primary completion
- Mar 31, 2023
- Completion date
- Mar 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 202
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gossamer Bio Inc.Lead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Pancreatic Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Small Cell Lung Carcinoma
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.